Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña






Scientific News Boston Scientific Still Expects Axonics Deal To Close This Year, Posts Street Beating Q3

Search Related Content

Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Still Expects Axonics Deal To Close This Year, Posts Street Beating Q3 is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.
Search RobinsPost News & Noticias


Scientific News Boston Scientific Still Expects Axonics Deal To Close This Year, Posts Street Beating Q3 | RobinsPost News & Noticias

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth


Wall Street expects a year-over-year increase in earnings on higher revenues when Boston Scientific (BSX) reports results for the quarter ended September 2025. While this widely-known consensus ... Read More

Boston Scientific: Q3 Earnings Snapshot


MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Boston Scientific Corp. (BSX) on Wednesday reported third-quarter profit of $755 million. On a per-share basis, the Marlborough, Massachusetts-based ... Read More

Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst


On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion. The medical technology giant reported ... Read More

Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript


Good morning, and welcome to the Boston Scientific Third Quarter 2025 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to ... Read More

Boston Scientific rises as cardiology sales drive Q3 beat, guidance boost


Boston Scientific (NYSE:BSX) traded higher on Wednesday after the MedTech giant exceeded Street forecasts with its Q3 2025 results and boosted its full-year outlook following better-than-expected ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus